Recent Articles by Keith Speights
By Keith Speights | July 17, 2018 |
The healthcare giant has stumbled lately, but J&J still has plenty to offer investors.
By Keith Speights | July 05, 2018 |
This stock is a cash cow with a strong moat and great growth prospects.
By Keith Speights | June 13, 2018 |
Newly identified potential issues with CRISPR-Cas9 gene editing aren't as worrisome as you might think.
By Keith Speights | June 12, 2018 |
These stocks have what it takes to help meet your financial needs in retirement beyond what Social Security can provide.
By Keith Speights | June 07, 2018 |
Which cloud-based healthcare technology stock wins in a head-to-head matchup?
By Keith Speights | June 06, 2018 |
These two drug stocks have a lot to offer income investors and value investors.
By Keith Speights | June 05, 2018 |
Here's why terrific results for a revolutionary new cancer therapy left investors unsatisfied.
By Keith Speights | June 01, 2018 |
These hot stocks are more alike than they might appear at first glance.
By Keith Speights | May 25, 2018 |
This biotech stock is skyrocketing. Here's why -- maybe.
By Keith Speights | May 23, 2018 |
Which big pharma stock wins in a head-to-head match-up?